Core Viewpoint - The company, Opcon Vision (300595.SZ), will disclose its third-quarter report on October 25, and investors are advised to check the report for specific operational details [2] Group 1 - As of October 10, 2025, the total number of shareholders for the company is 61,458 [2]

Core Viewpoint - The stock of Opcon Vision has shown fluctuations in recent trading days, with a slight increase on September 30, 2023, despite a year-to-date decline of 9.11% [1][2]. Company Overview - Opcon Vision Technology Co., Ltd. was established on October 26, 2000, and went public on January 17, 2017. The company is located in Hefei, Anhui Province, and specializes in the research, production, and sales of optical products and related services [2]. - The main revenue sources for the company include: hard contact lenses (40.86%), other optical products and technical services (21.52%), medical services (19.89%), nursing products (12.57%), non-optical products (4.60%), and other (0.55%) [2]. Financial Performance - For the first half of 2025, Opcon Vision reported a revenue of 871 million yuan, a year-on-year decrease of 1.42%, and a net profit attributable to shareholders of 250 million yuan, down 22.93% year-on-year [2]. - Since its A-share listing, the company has distributed a total of 897 million yuan in dividends, with 526 million yuan distributed over the past three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders for Opcon Vision was 61,000, a decrease of 1.56% from the previous period. The average circulating shares per person increased by 1.58% to 10,957 shares [2]. - Major institutional shareholders include Huabao Zhongzheng Medical ETF, Yifangda Growth Enterprise Board ETF, and Southern Zhongzheng 500 ETF, with all showing increases in their holdings compared to the previous period [3].

Group 1 - The core viewpoint of the article is that the new national centralized procurement policy does not prioritize lowest price procurement, which may enhance the competitive edge of companies with advanced technologies like DK185 [2] - The company, Opcon Vision (300595.SZ), indicated that its DK185 product has not yet participated in centralized procurement but is experiencing good market promotion and gradually increasing sales [2]

Group 1 - The core point of the article is that Opcon Vision (300595) announced on the evening of September 25 that the company and its subsidiaries have no overdue external guarantees, no guarantees involved in lawsuits, and no losses incurred due to guarantees resulting in adverse judgments [1] Group 2 - The announcement indicates a stable financial position for the company, as it highlights the absence of any legal or financial liabilities related to guarantees [1] - This information may positively influence investor confidence in the company's operational integrity and risk management practices [1] - The lack of overdue guarantees and legal issues suggests that the company is maintaining a prudent approach to its financial commitments [1]

Group 1 - The company, Opcon Vision, announced the convening of its first extraordinary general meeting of shareholders on July 22, 2025, to review the proposal for changing registered capital and amending the Articles of Association [1] - The company held its second extraordinary general meeting of shareholders on September 9, 2025, to review the proposal for amending the Articles of Association and handling the business registration change [1] - The company has completed the business registration and filing procedures, obtaining a new business license issued by the Market Supervision Administration of Hefei City [1]

证券代码：300595 证券简称：欧普康视 公告编号：2025-082 欧普康视科技股份有限公司 关于控股子公司为其子公司提供担保的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、担保概述 欧普康视科技股份有限公司（以下简称"公司"）全资子公司欧普康视投资 有限公司（以下简称"欧普投资"）的控股子公司马鞍山梦戴维医疗科技有限公 司（以下简称"马鞍山梦戴维"，担保方）的控股子公司马鞍山康视眼科医院有 限公司（以下简称"马鞍山康视医院"，被担保方 1）、和县康视眼科医院有限 公司（以下简称"和县康视医院"，被担保方 2）拟向合作银行分别申请总额不 超过人民币 700 万元，100 万元的授信额度，授信期限 1 年，马鞍山梦戴维同意 为马鞍山康视医院、和县康视医院向上述合作银行分别申请总额不超过人民币 700 万元、100 万元融资事项提供连带责任保证担保。 根据《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规 范运作》等相关规定，本次担保事项属于上市公司控股子公司为上市公司合并报 表范围内的法人提供担保，已履行子公司内部审批程序，无需提 ...

证券代码：300595 证券简称：欧普康视 公告编号：2025-083 欧普康视科技股份有限公司 关于完成工商变更登记并换发营业执照的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 欧普康视科技股份有限公司（以下简称"公司"）于 2025 年 7 月 22 日召开 2025 年第一次临时股东大会审议通过了《关于变更注册资本并修订〈公司章程〉 的议案》，于 2025 年 9 月 9 日召开 2025 年第二次临时股东大会审议通过了《关 于修订〈公司章程〉并办理工商变更登记的议案》。具体内容详见公司于 2025 年 7 月 5 日、2025 年 8 月 23 日在巨潮资讯网（http://www.cninfo.com.cn）披 露的《关于变更注册资本并修订〈公司章程〉的公告》（公告编号：2025-052） 《关于修订〈公司章程〉及修订、制定公司部分治理制度的公告》（公告编号： 2025-071）。 近日，公司完成了工商变更登记及备案手续，并取得了合肥市市场监督管理 局换发的《营业执照》。变更后的《营业执照》登记信息如下： 1、名称：欧普康视科技股份有限公司 ...

Core Viewpoint - As of September 19, 2025, the total number of shareholders for Opucon Vision (300595) is reported to be 61,008 [1] Company Summary - Opucon Vision has engaged with investors through an interactive platform, providing transparency regarding its shareholder count [1]

Core Viewpoint - The company, Opcon Vision, has received acceptance from the National Medical Products Administration for its medical device product "Hydrogen Peroxide Care Solution" registration application [2] Group 1 - The announcement was made on the evening of September 22 [2] - The acceptance notification indicates progress in the regulatory approval process for the company's medical device [2]

Core Viewpoint - The company has received acceptance for the registration application of its medical device product "Hydrogen Peroxide Care Solution" by the National Medical Products Administration, indicating progress in regulatory approval [1] Group 1: Product Details - The product is intended for cleaning, disinfecting, protein removal, and storage of hard contact lenses, classified as a domestic Class III medical device [1] - The current stage of the registration process is acceptance of the application, with subsequent technical review required [1] Group 2: Market Context - Similar products are already available in the domestic market and are experiencing continuous growth in production and sales [1] Group 3: Financial Impact - The acceptance of the registration application will not impact the company's recent performance, and the future impact on performance remains uncertain [1]